About Shionogi
About Shionogi
Message from Top Management
Brand Statement
Shionogi's Strength
Management Philosophy
Company Profile
Management Strategy
Operations
Compliance
Group Companies
Corporate Governance
Policies
History
History of Infectious Diseases
SHIONOGI Journal
Sustainability
Sustainability
Material Issues (Materiality)
Address the problem of antimicrobial resistance (AMR)
Environment
Society
Governance
Access to Healthcare
Stakeholder Engagement
Annual Report / Integrated Report / Environment Report
Data
External Evaluation
About United Nations Global Compact
Information related to infectious diseases
Innovation
Innovation
R&D
Partnering
Pipeline
IP Strategy
SHIONOGI's Vaccine Initiatives
Adjuvant
Wastewater-based Epidemiology Surveillance Service
News
Investors
Investors
Top Message
Latest IR Information
IR Library
Management Policy
Shareholder Information
Individual Investors
Sustainability
Financial Highlights
IR Calendar
Contact Us
Careers
Search
English
Worldwide
HOME
News
SHIONOGI ANNOUNCES THAT NALDEMEDINE MET THE PRIMARY ENDPOINT IN ITS FIRST JAPANESE PHASE 3 STUDY FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN CANCER PATIENTS
Release
2015/06/24
SHIONOGI ANNOUNCES THAT NALDEMEDINE MET THE PRIMARY ENDPOINT IN ITS FIRST JAPANESE PHASE 3 STUDY FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN CANCER PATIENTS
